4 min read
ASCO 2026: RAS Is No Longer Undruggable
For decades, oncologists and drug developers shared an undeniable truth: KRAS – one of the most commonly mutated genes...
Meet Veristat in Boston at the Pharmacovigilance USA Conference
2-3 May 2024
We are delighted to announce that Veristat will be attending the 35th annual Pharmacovigilance (PV) USA conference. Don´t miss the opportunity to meet our team of highly experienced PV professionals, dedicated to ensuring the fulfillment of your regulatory requirements through sound processes and efficient systems to reduce your risk.
Veristat supports successful pre-approval and post-market PV and Medical Information (MI) expertise for pharmaceutical drugs, (both branded and generic), biologics, radiopharmaceutical drugs, natural health products, and medical devices.
Be certain, be inspection-ready, and keep your patients protected - with Veristat Pharmacovigilance experts on your side. Connect with us at the conference and learn more about how Veristat is making a difference.
Schedule A Meeting
Veristat team member, Alan Braverman, Senior Business Development Director, will be at the venue, ready to listen to your needs and share more about Veristat’s expertise. Arrange a meeting today! Complete the form on the right side of this page and we will confirm the date and time.
Conference Details
Website: 35th Pharmacovigilance USA 2024
Schedule A Meeting
Meet with us at the Pharmacovigilance USA Conference 2024 by filling out the form below.
Event Topics:
10 min read
Monthly FDA Guidance and Regulatory News Review - May 2026
Jun 12, 2026 Veristat Blog
This May 2026 regulatory update highlights multiple guidances issued by the FDA across cell and gene therapy, clinical...